Mao et al. applied the enantio and retro-enantio approach to the AE peptide (FALGEA) to target the epidermal growth factor receptor (EGFR) and the mutation variant III (EGFRvIII) for glioma treatment [60]. The gene discussed is EGFR; the disease is central nervous system cancer.